STEP 1, STEP 4 and SURMOUNT-4 show what really happens when patients stop GLP-1 peptides. Tapering, maintenance dosing, and the lifestyle handoff that protects results.
Avocados, eggs, olive oil, oats, and Greek yogurt are the five foods with peer-reviewed evidence for naturally boosting GLP-1, Ozempic's hormone.
Tirzepatide drives an average 22.5% body-weight loss in trials — but stopping the drug leads to roughly 14% regain in a year, even with diet and exercise.
Most patients on Ozempic, Wegovy, or Zepbound hear about nausea and stop there. The full safety profile includes lean muscle loss, sulfur burps, gallstones, NAION vision risk, anesthesia warnings, and more. A research-grounded guide to what gets left out of the 15-minute appointment.
How the three big GLP-1 drugs really compare on weight loss, cardiovascular benefit, dosing schedule, side effects, and cost.
SURMOUNT-5 settled the indirect-comparison era. Here is what the head-to-head trial actually showed about tirzepatide versus semaglutide for fat loss.
From semaglutide to retatrutide and tesamorelin: the seven peptides reshaping obesity care, what trials really show, and what to ask before starting.
Tesamorelin is trending as a midlife belly-fat peptide, but the FDA approval, the 18% visceral-fat number, and the cancer warnings tell a more complicated story for women over 40.
Plateaus on GLP-1 drugs are biology, not failure. Here is an evidence-honest review of the five "stacks" people consider, including which ones have trial data.
What 90 days of semaglutide actually changes — pulled from STEP-1, STEP-4, and real-world cohorts, not marketing photos.
Retatrutide produced 28.7% mean weight loss in its first Phase 3 readout. Here's what TRIUMPH-4 actually showed and what it didn't.
STEP 1, STEP 4 and SURMOUNT-4 show what really happens when patients stop GLP-1 peptides.
Tapering, maintenance dosing, and the lifestyle handoff that protects results.
The goal isn’t to be comfortable with change — it’s to be comfortable with one small change, on a schedule, held for a year.
We’re recording with NotebookLM. Expect a deep-dive and a short-form version of each issue’s best essays, delivered to your favorite podcast app when we launch.